Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systemic Embolism Clear all
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
AFSW Guided DOAC, Continuous DOAC therapy
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 85 Years
Enrollment
5,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
93
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 22, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
REGN7508, REGN9933, Apixaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Dothan, Alabama • Fairhope, Alabama • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 5:44 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Raynaud's Syndrome
Interventions
botulinum toxin A
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced May 22, 2026, 5:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Neurocognitive Dysfunction
Interventions
Transseptal Aortic Approach Catheter Ablation Procedure, Retrograde Aortic Approach Catheter Ablation Procedure
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Neoplasms
Interventions
Rivaroxaban, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
70
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Alprostadil, Placebo
Drug · Other
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Industry
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced May 22, 2026, 5:44 AM EDT
Not listed Phase 3 Interventional
View directory record Official record
Conditions
Raynaud Disease
Interventions
0.9% nitroglycerin in TAM cream, vehicle cream
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Redwood City, California • Farmington, Connecticut • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2010 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Neoplasms
Interventions
Rosuvastatin, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced May 22, 2026, 5:44 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Stroke, Systemic Embolism, VTEt and VTEp
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
Interventions
MQX-503
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Timeline
2006
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated May 29, 2007 · Synced May 22, 2026, 5:44 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions
Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Topical organogel with nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2007 · Synced May 22, 2026, 5:44 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial, Major Bleeding
Interventions
Home Monitoring Guided OAC, Physician-Directed OAC
Drug
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced May 22, 2026, 5:44 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Stroke, Atrial Fibrillation, Embolism
Interventions
warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
21 Years and older
Enrollment
21,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
316
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced May 22, 2026, 5:44 AM EDT
Terminated Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
CREST Syndrome, Peripheral Vascular Disease, Raynaud Disease, Scleroderma, Diffuse
Interventions
liposomal bupivacaine
Drug
Lead sponsor
Jose Soberon, MD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced May 22, 2026, 5:44 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Diabetes, Cardiovascular Disease, Epilepsy, Migraine, Neurological Disorders, Cancer, Bariatric Surgery Candidate, Organ or Tissue Transplant; Complications, Lupus Erythematosus, Systemic, Other Hematologic Conditions, Other Venous Embolism and Thrombosis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced May 22, 2026, 5:44 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Stroke
Interventions
Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device
Device
Lead sponsor
Coherex Medical
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
warfarin, Dabigatran dose 1, Dabigatran dose 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
18,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
374
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 286 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Raynaud Phenomenon Secondary to Systemic Sclerosis
Interventions
Placebo IV infusion, Iloprost Injection, for intravenous use
Drug
Lead sponsor
Civi Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced May 22, 2026, 5:44 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Systemic Sclerosis, Fatigue, Raynaud Phenomenon
Interventions
Apollo
Device
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced May 22, 2026, 5:44 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Temanogrel, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Placebo IV infusion, Iloprost Injection, for intravenous use
Drug
Lead sponsor
Civi Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced May 22, 2026, 5:44 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Prevention of Stroke or Systemic Embolism, Atrial Fibrillation
Interventions
Asundexian (BAY2433334), Apixaban, Asundexian matching placebo, Apixaban matching placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14,830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
163
States / cities
Dothan, Alabama • Fairhope, Alabama • Mobile, Alabama + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced May 22, 2026, 5:44 AM EDT